doi: 10.3389/fnut.2025.1615671 Received 21 April 2025 Accepted 29 July 2025 Published 13 August 2025 Volume 12 - 2025 Edited by Ismael San Mauro Martn, CINUSA Group, Spain Reviewed by Simone Birgit Bayer, University of Otago, Christchurch, New Zealand Emanuela Ribichini, Sapienza University of Rome, Italy Aleksandar Sic, Advocate Illinois Masonic Medical Center, United States Updates Copyright 2025 Khan, Brnstad, Hillestad, Steinsvik, Hausken, Berentsen and Lied
These individualized decisions are difficult to make without close provider engagement, which reinforces the value proposition of IVIM ongoing monitoring model even after the active weight loss phase has concluded
What is CJC-1295 and how does it work
Can you take a GLP-1 booster while on Ozempic or Wegovy
Some patients experience mild redness, warmth, or slight tenderness at the injection site within hours of administration
This is why these medications are effective for type 2 diabetes management alongside weight loss